MicroRNA market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product & Service (Products, Consumables, Services), By Application (Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease, Others), By End User (Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Other), by region, a
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationMicroRNA market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product & Service (Products, Consumables, Services), By Application (Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease, Others), By End User (Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Other), by region, a
| Forecast Period | 2024-2028 |
| Market Size (2022) | USD 1548.17 Million |
| CAGR (2023-2028) | 12.19% |
| Fastest Growing Segment | Services |
| Largest Market | North America |
Market Overview
Global MicroRNA Market has valued at USD 1548.17 Million in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 12.19% through 2028. MicroRNAs (miRNAs) are a class of small RNA molecules that play a significant role in gene regulation. They are a fundamental part of the complex molecular machinery that controls gene expression and are involved in various biological processes in both plants and animals, including humans. MicroRNAs are typically short RNA molecules, usually composed of around 20 to 22 nucleotides. They have a characteristic stem-loop structure. MicroRNAs are transcribed from DNA sequences into a longer precursor molecule called pri-miRNA by RNA polymerase. This pri-miRNA is processed in the cell nucleus by the enzyme Drosha, resulting in a shorter hairpin-shaped molecule called pre-miRNA. The pre-miRNA is then transported to the cytoplasm and further processed by Dicer, an RNA-processing enzyme, into a double-stranded RNA molecule. One of the strands, known as the mature miRNA, is incorporated into a protein complex called the RNA-induced silencing complex (RISC).
Key Market Drivers
Advancements in Genomic Research
One of the initial breakthroughs in microRNA research was the discovery of these small RNA molecules. In the early 2000s, researchers identified the existence of a large number of microRNAs in various species, including humans. This discovery opened the door to further exploration of their functions. The advent of high-throughput sequencing technologies, such as next-generation sequencing (NGS), has revolutionized microRNA research. These technologies enable the rapid and cost-effective profiling of microRNA expressions in various tissues and under different conditions. The establishment and continuous updating of miRBase, a comprehensive database of microRNA sequences, annotations, and target predictions, have provided a valuable resource for researchers worldwide. This database has supported the standardization and classification of microRNAs. Advancements in functional genomics and molecular biology techniques have allowed researchers to investigate the roles of specific microRNAs in gene regulation. These studies involve techniques like CRISPR-Cas9 for gene editing and gene knockout experiments to determine the effects of microRNA dysregulation. Single-cell RNA sequencing has enabled the study of microRNA expression at the single-cell level. This technology has provided insights into the heterogeneity of microRNA expression within tissues and the role of microRNAs in individual cells.
Comparative genomics has enabled the study of microRNAs across different species. Researchers have identified conserved and species-specific microRNAs, shedding light on their evolutionary significance and functional conservation. Computational tools and databases have been developed to predict microRNA target genes and their functions. These tools assist researchers in understanding the regulatory networks in which microRNAs are involved. Research has extended beyond microRNAs to explore interactions and crosstalk with other non-coding RNAs, such as long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs). These interactions can significantly impact gene regulation and are an area of active research. Investigations into the epigenetic regulation of microRNAs, including DNA methylation and histone modifications, have provided insights into how microRNA expression is controlled and how it can be dysregulated in diseases. Advances in genomic research have paved the way for clinical applications of microRNAs as diagnostic biomarkers, prognostic indicators, and therapeutic targets in various diseases, including cancer, cardiovascular diseases, and neurological disorders. RNA-Seq and small RNA sequencing techniques have allowed researchers to analyze the transcriptome comprehensively, including the identification and quantification of microRNAs. This factor will help in the development of the Global MicroRNA Market.
Growing Emphasis on Biomarker Discovery
MicroRNAs are being increasingly recognized as valuable biomarkers for the diagnosis and monitoring of various diseases, including cancer, cardiovascular diseases, neurodegenerative disorders, and infectious diseases. They can serve as non-invasive or minimally invasive diagnostic tools, enabling earlier and more accurate disease detection. Biomarker discovery, including microRNA profiling, contributes to the development of personalized medicine. By analyzing the microRNA profile of an individual, healthcare providers can tailor treatment plans to the specific characteristics of the patient's disease. This approach can improve treatment efficacy and reduce adverse effects. Biomarkers, such as microRNAs, are critical in drug development and clinical trials. They can be used to identify suitable patient populations for clinical studies, monitor treatment responses, and assess the safety and efficacy of new therapies. This accelerates the drug development process and reduces the cost of clinical trials. MicroRNAs are not only valuable for disease diagnosis but also for predicting disease prognosis and response to therapy. This information is essential for determining the likely course of a disease and for optimizing treatment strategies.
Biomarkers, including microRNAs, are used in companion diagnostics, which are tests developed alongside specific therapies to identify patients who are most likely to benefit from the treatment. This approach is increasingly important in precision medicine. MicroRNAs can be detected in various bodily fluids, such as blood, urine, and saliva. This non-invasive nature of microRNA-based biomarker testing makes it convenient and well-tolerated by patients, enhancing its appeal for both routine screenings and disease management. Early detection of diseases is often crucial for successful treatment outcomes. MicroRNA biomarkers are used in the development of tests that can identify diseases at their earliest, most treatable stages. Biomarker-based tests, including those utilizing microRNAs, are employed to monitor the progression of diseases over time. This information guides treatment decisions and helps assess the effectiveness of therapeutic interventions. Biomarker discovery is a critical aspect of research, enabling scientists to uncover new associations between microRNAs and diseases. This drives further investigation and innovation in the field. The demand for microRNA-based biomarker discovery fuels growth in the microRNA market. Companies invest in research, product development, and commercialization to meet the demand for biomarker-related services and products. This factor will pace up the demand of the Global MicroRNA Market.
Increasing Development of RNA-Based Therapeutics
MicroRNAs have shown promise as therapeutic agents due to their role in gene regulation. They can be harnessed to modulate the expression of specific genes, making them potential candidates for treating a wide range of diseases, including cancer, cardiovascular disorders, and genetic conditions. MicroRNA-based therapeutics can be highly specific in their action, targeting the expression of genes or pathways associated with a disease. This precision allows for more effective and less toxic treatments, as they spare healthy cells from harm. MicroRNA-based therapeutics have broad applications. They can be used for oncology, cardiovascular medicine, neurodegenerative diseases, metabolic disorders, and more. The versatility of microRNAs as therapeutic agents contributes to their high demand. RNA-based therapeutics, including microRNA mimics and anti-miRNA agents, represent innovative approaches to disease management. They can address diseases that were previously challenging to treat with traditional therapies. MicroRNA-based therapeutics align with the principles of precision medicine. By analyzing a patient's microRNA profile, healthcare providers can tailor treatments to the specific molecular characteristics of the disease, enhancing their effectiveness.
The development of microRNA-based therapeutics has driven a demand for services related to pre-clinical and clinical testing. Companies require diagnostic tools, biomarker identification, and other services to advance their therapeutic candidates through trials. The potential of microRNA-based therapeutics has attracted significant investment and funding from venture capital firms, government agencies, and pharmaceutical companies. This financial support has accelerated research and development efforts in this field. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), have provided guidance and support for the development of RNA-based therapeutics, including microRNAs. This regulatory clarity has facilitated the clinical translation of these therapies. Collaborations between biotechnology companies, pharmaceutical firms, and academic institutions have been pivotal in advancing microRNA-based therapeutics. These partnerships combine scientific expertise and resources to drive innovation. The competitive landscape of the biotechnology and pharmaceutical sectors has led to increased innovation and product development. The pursuit of novel therapies and approaches, including microRNA-based treatments, drives market growth. Many diseases, particularly those with complex genetic components, still lack effective treatments. The potential of microRNA-based therapeutics to address these unmet medical needs generates significant interest and demand. This factor will accelerate the demand of the Global MicroRNA Market.
Key Market Challenges
Standardization
MicroRNA research and analysis involve various analytical platforms, including quantitative polymerase chain reaction (qPCR), microarray technology, and next-generation sequencing (NGS). Each platform has its own protocols and techniques, making it challenging to ensure consistency and comparability of results. Variability in sample preparation methods, such as RNA extraction and quality control, can lead to differences in microRNA profiles. Standardizing these steps is critical to obtaining reliable and reproducible results. The analysis and interpretation of microRNA data can vary among researchers and laboratories. Standardizing data analysis methods and reporting criteria is essential to facilitate data sharing and comparison. The lack of standardized reference materials, including well-characterized microRNA standards, hinders the accuracy and reliability of microRNA quantification. Having validated reference materials is crucial for quality control. Researchers need standardized normalization procedures to account for variations in microRNA expression levels due to sample differences and technical factors. Lack of consistent normalization methods can lead to inaccurate results. Standardized quality control measures for assessing the integrity and purity of RNA samples are essential to ensure the reliability of microRNA data. Variability in quality control practices can impact data quality. When using microRNAs as biomarkers, their validation can be a challenge. There is a need for standardized guidelines and criteria for validating microRNA biomarkers, including sensitivity, specificity, and reproducibility.
Ethical and Privacy Concerns
MicroRNA profiles can provide insights into an individual's genetic and molecular characteristics. Concerns arise about the potential misuse of this information, such as genetic discrimination by employers, insurers, or other entities. Researchers and healthcare providers must ensure that individuals participating in microRNA studies or diagnostic tests provide informed consent. This involves explaining the potential risks and benefits, as well as how their data will be used and shared. The storage and transmission of microRNA data must be secure to protect against unauthorized access and data breaches. Ensuring robust data security measures is essential to safeguard sensitive genetic information. Biobanks that store biological samples for research purposes must adhere to ethical standards and consent guidelines. The use of stored samples for microRNA research should be clearly disclosed and controlled. It can be challenging to maintain patient anonymity when working with microRNA data, especially in small populations or rare diseases. Researchers must implement measures to protect patient privacy. Determining who owns and controls the microRNA data and results can be ethically complex. Balancing the interests of researchers, institutions, and patients is a challenge. The potential dual-use nature of microRNA research, where knowledge and technologies can be used for both beneficial and harmful purposes, poses ethical dilemmas. Researchers must consider the responsible conduct of research.
Key Market Trends
Personalized Medicine
MicroRNAs are increasingly being identified as valuable biomarkers that can help stratify patients into different subgroups based on their microRNA profiles. This allows for more precise diagnoses and treatment plans. MicroRNA-based diagnostics are being developed to detect specific microRNA patterns associated with diseases. These diagnostics enable early and accurate disease detection, improving patient outcomes. The molecular information provided by microRNA profiles can guide healthcare providers in selecting the most appropriate treatment options for patients. This is particularly relevant in cancer treatment, where different tumors may respond differently to therapies. MicroRNAs can be used to predict disease progression, treatment response, and prognosis. This information helps healthcare providers make informed decisions about treatment strategies and interventions. MicroRNA profiles can influence how individuals metabolize medications and respond to treatments. Pharmacogenomic research involving microRNAs can help determine the most effective and safe drug regimens for patients. MicroRNAs are being explored as therapeutic agents for personalized medicine. By modulating the expression of specific microRNAs, researchers aim to develop tailored treatments for various diseases and genetic disorders. MicroRNA-based risk assessment can identify individuals who may have a higher predisposition to certain diseases. This information can guide preventive measures and early intervention. MicroRNA profiles can be used to monitor the progression of diseases over time. Regular monitoring enables adjustments to treatment plans and interventions as needed.
Segmental Insights
Product & Service Insights
In 2022, the Global MicroRNA Market largest share was held by services segment and is predicted to continue expanding over the coming years.
Application Insights
In 2022, the Global MicroRNA Market largest share was held by cancer segment and is predicted to continue expanding over the coming years.
End-User Insights
In 2022, the Global MicroRNA Market largest share was held by
Regional Insights
The North America region dominates the Global MicroRNA Market in 2022.
Recent Developments
- In January 2023, Bio-TechneCorporation has expanded its Advanced Cell Diagnostics (ACD)-branded RNAscopein situ hybridization (ISH) portfolio by introducing the RNAscope PlussmRNA-RNA detection assay. This new assay allows for the simultaneousfluorescent detection of a small regulatory RNA alongside three target RNAs orRNA biomarkers in the same tissue section, all with single-cell and subcellularprecision. The assay is designed to be easily scalable, making it suitable forlarge-scale studies. It will be available for use on the Leica Bond Rx platformand can also be performed manually. Small regulatory RNAs, such as miRNAs, play a crucial role in regulatinghuman health and have been associated with a wide spectrum of diseases.Oligonucleotide therapies, which include antisense oligonucleotides (ASOs) andRNA interference (RNAi), represent a unique category of gene therapies. Thesetherapies have the potential to deliver highly targeted and long-lastingtherapeutic effects by leveraging similar cellular mechanisms. Thesetherapeutic nucleic acids can be harnessed to control the expression andfunction of specific target genes, paving the way for personalized treatmentsfor inherited or acquired diseases that were previously resistant toconventional therapies.
Key Market Players
- Thermo Fisher Scientific,Inc.
- Horizon Discovery Ltd.
- OriGene Technologies, Inc.
- QIAGEN
- GeneCopoeia, Inc.
- Merck KGaA
- Miltenyi Biotec
- Sistemic Scotland Limited
- SeqMatic LLC
- Biodynamics Laboratory Inc.
| By Product & Service | By Application | By End-User | By Region |
|
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy